💉 Pfizer India Surges 9.4% to ₹4,890 — But Is ₹566 Cr FY25 Profit Enough to Justify the Buzz?
📌 At a glance:
FY25 PAT: ₹566 crore (–15% YoY)
FY25 Revenue: ₹2,479 crore (–2.6%)
Q4 PAT: ₹126 crore (–21% YoY)
CMP: ₹4,890.00 (+9.44% today)
🧬 About the Company
Pfizer Ltd is the Indian arm of the global pharma giant. It operates primarily in branded formulations including vaccines, anti-infectives, pain management, and cardiology. Unlike its global parent, it doesn’t manufacture the COVID vaccine in India.
